替罗非班对冠脉介入中慢血流及无复流的疗效观察

The Curative Effect of Tirofiban on the Patients with Slow Flow and No Reflow During PCI Procedure

目的:观察冠状动脉内注入替罗非班治疗冠状动脉介入术中慢血流及无复流现象的效果。方法:对冠状动脉介入术中出现的37例慢血流,33例无复流,依次给予冠脉内注入硝酸甘油,维拉帕米,腺苷和替罗非班,观察靶血管前向血流的TIMI血流分级。结果:替罗非班明显改善冠状动脉介入术中慢血流及无复流的TIMI血流,慢血流的有效率为90%(27/30),优于硝酸甘油10.8%(4/37),维拉帕米3%(1/33)和腺苷6.2%(2/32),P<0.01;无复流的有效率为89.3%(25/28),优于硝酸甘油3%(1/33),维拉帕米3.1%(1/32)和腺苷9.7%(3/31),P<0.01。结论:冠状动脉内注入替罗非班对冠状动脉介入术中出现的慢血流及无复流现象有效。

Objective： To observe the clinical effect of platclct GP Ⅱ b/Ⅲa recepter antagonist, tirofiban on patients with slow flow and no reflow during percutaneous coronary intervention （PCI） procedure. Method： Thirty-seven eases of slow flow patients and thirty-three cases of no reflow patients during PCI procedure were infused with nitroglycerin, verapamil, adenosine and tirofiban in turn, and the target vessel TIMI flow was graded accordingly. Result： Tirofiban improved target vessel TIMI flow more significantly than nitroglycerin, verapamil and adenosine. Their effective rates in slow flow were 90% （27/30）, 10.8% （4/37）, 3% （ 1/33 ）and 6.2% （2/32）,P〈0.01;in no reflow cases, the rates were 89.3%（25/28）,3%（1/33）,3.1%（l/32）and 9.7%（3/31）,P〈0.01. Conclusion： Tirofiban has definite effect on patients with slow flow and no reflow during PCI procure and further investigation is necessary.